Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will assess the safety and efficacy of a new liquid anti-adhesion device, JOCOAT(TM) APN-3003 in patients undergoing knee anterior cruciate ligament reconstruction (ACLR) surgery.
This is a single-center, prospective study. Safety and clinical outcomes will be compared with historical controls from enrolled study site patients from NCT03935750 (STABILITY 2) which has evaluated outcomes following ACL rupture in young athletes.
A maximum of 24 patients aged 15-25 years undergoing primary anatomic ACLR with quadriceps tendon (QT) graft following a standardized surgical treatment algorithm will be enrolled. All patients will receive JOCOAT(TM) APN-3003 at the end of their surgery.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| JOCOAT(TM) APN-3003 | Experimental | Intra-articular injection |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| JOCOAT(TM) APN-3003 | Device | 10 mL of JOCOAT(TM) APN-3003 is applied at the end of surgery |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety of JOCOAT(TM) APN-3003 as measured by number and severity of adverse device effects and serious adverse device effects | The number of severe and serious adverse events in treated subjects from this study is compared with the number seen in historical controls | 3 months after surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Exploratory efficacy of JOCOAT(TM) APN-3003 as measured by comparing range of motion (ROM) pre-operatively and post-operatively | Range of motion is measured pre-operative and post-operatively and compared | 3 months after surgery |
| Patient recovery as measured by Patient Reported Outcome Measures (KOOS) |
Not provided
Pre-operative Inclusion Criteria:
Understand and be able to follow the requirements of the protocol including personally signing and dating an REB approved Informed Consent Form prior to undergoing any protocol related procedures
Subjects aged 15 to 25 years with an ACL-deficient knee undergoing primary ACLR
Subjects with skeletal maturity (i.e. closed epiphyseal growth plates on standard knee radiographs)
At least two of the following factors that are associated with a high risk of graft failure:
Biological females have a negative pregnancy test within 4 days of initial surgery
Is willing, able and likely to fully comply with clinical trial procedures and restrictions including follow-ups
Pre-operative Exclusion Criteria:
Intra-operative Inclusion Criteria:
- Patient undergoes primary anatomic anterior cruciate ligament reconstruction surgery with quadriceps tendon (QT) graft
Intra-operative Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000267 | Tissue Adhesions |
| ID | Term |
|---|---|
| D002921 | Cicatrix |
| D005355 | Fibrosis |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
All patients in this study will receive the investigational treatment. Safety and clinical outcomes from this study will be compared with historical controls from enrolled study site patients from NCT03935750.
Not provided
Not provided
Not provided
Not provided
Patient reported outcome measure results (Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire) pre-operatively and post-operatively are compared with historical controls |
| Up to 12 months after surgery |
| Patient recovery as measured by Patient Reported Outcome Measures (PASS) | Patient reported outcome measure results (Patient-Acceptable Symptom States (PASS) questionnaire) pre-operatively and post-operatively are compared with historical controls | Up to 12 months after surgery |
| Patient recovery as measured by Patient Reported Outcome Measures (EQ-5D-5L) | Patient reported outcome measure results (EQ-5D-5L questionnaire) pre-operatively and post-operatively are compared with historical controls | Up to 12 months after surgery |